NYSE:KDMN - Kadmon Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.47 +0.18 (+7.86 %) (As of 12/17/2018 06:00 AM ET)Previous Close$2.47Today's Range$2.22 - $2.485052-Week Range$1.88 - $5.86Volume764,354 shsAverage Volume521,148 shsMarket Capitalization$279.43 millionP/E Ratio-1.74Dividend YieldN/ABeta3.58 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; ROCK inhibitor platform, a rho-associated coiled-coil kinase inhibitor, which is in preclinical development to treat specific fibrotic and neurodegenerative diseases; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Chiromics, LLC; MeiraGTx Limited; AbbVie Inc.; Zydus Pharmaceuticals USA, Inc.; Jinghua Pharmaceutical Group Co., Ltd.; and Camber Pharmaceuticals, Inc. The company is headquartered in New York, New York. Receive KDMN News and Ratings via Email Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:KDMN Previous Symbol CUSIPN/A Webwww.kadmon.com Phone212-308-6000 Debt Debt-to-Equity Ratio0.32 Current Ratio6.64 Quick Ratio6.58 Price-To-Earnings Trailing P/E Ratio-1.74 Forward P/E Ratio-3.13 P/E GrowthN/A Sales & Book Value Annual Sales$12.26 million Price / Sales22.79 Cash FlowN/A Price / Cash FlowN/A Book Value($0.49) per share Price / Book-5.04 Profitability EPS (Most Recent Fiscal Year)($1.42) Net Income$-79,770,000.00 Net Margins-1,176.75% Return on Equity-253.82% Return on Assets-55.79% Miscellaneous Employees101 Outstanding Shares113,130,000Market Cap$279.43 million OptionableOptionable Kadmon (NYSE:KDMN) Frequently Asked Questions What is Kadmon's stock symbol? Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN." How were Kadmon's earnings last quarter? Kadmon Holdings Inc (NYSE:KDMN) issued its earnings results on Thursday, August, 9th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.50. The company earned $0.36 million during the quarter, compared to analyst estimates of $0.90 million. Kadmon had a negative return on equity of 253.82% and a negative net margin of 1,176.75%. View Kadmon's Earnings History. When is Kadmon's next earnings date? Kadmon is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Kadmon. What price target have analysts set for KDMN? 4 Wall Street analysts have issued 12 month price targets for Kadmon's shares. Their forecasts range from $2.90 to $25.00. On average, they anticipate Kadmon's stock price to reach $13.2250 in the next twelve months. This suggests a possible upside of 435.4% from the stock's current price. View Analyst Price Targets for Kadmon. What is the consensus analysts' recommendation for Kadmon? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kadmon. What are Wall Street analysts saying about Kadmon stock? Here are some recent quotes from research analysts about Kadmon stock: 1. According to Zacks Investment Research, "Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. " (11/15/2018) 2. HC Wainwright analysts commented, "Our price target of $25 is based on a probability adjusted sum-of-parts $12 from KD025 in cGVHD + $12 from tesevatinib in PKD + $1 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller than anticipated commercial opportunity due to market sizing, competition, and pricing. Kadmon Holdings, Inc." (11/12/2018) Has Kadmon been receiving favorable news coverage? Media headlines about KDMN stock have trended somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kadmon earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are some of Kadmon's key competitors? Some companies that are related to Kadmon include Clovis Oncology (CLVS), Kiniksa Pharmaceuticals (KNSA), Apellis Pharmaceuticals (APLS), Uniqure (QURE), Deciphera Pharmaceuticals (DCPH), Retrophin (RTRX), Rhythm Pharmaceuticals (RYTM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Crinetics Pharmaceuticals (CRNX), Athenex (ATNX), ImmunoGen (IMGN) and Lexicon Pharmaceuticals (LXRX). Who are Kadmon's key executives? Kadmon's management team includes the folowing people: Dr. Harlan W. Waksal, Pres, CEO & Director (Age 65)Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 50)Mr. Kyle Carver, Controller & Principal Accounting OfficerDr. John L. Ryan, Chief Medical Officer & Exec. VP (Age 75)Wei Chen Ph.D., Associate Director of Immunology When did Kadmon IPO? (KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers. Who are Kadmon's major shareholders? Kadmon's stock is owned by many different of institutional and retail investors. Top institutional investors include Acuta Capital Partners LLC (6.54%), BlackRock Inc. (5.98%), Vanguard Group Inc. (4.22%), Vanguard Group Inc (4.22%), Marshall Wace North America L.P. (2.15%) and VHCP Management III LLC (2.11%). Company insiders that own Kadmon stock include Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal and Steven N Gordon. View Institutional Ownership Trends for Kadmon. Which major investors are selling Kadmon stock? KDMN stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Acuta Capital Partners LLC, EcoR1 Capital LLC, Marshall Wace North America L.P., Sphera Funds Management LTD. and Asymmetry Capital Management L.P.. View Insider Buying and Selling for Kadmon. Which major investors are buying Kadmon stock? KDMN stock was purchased by a variety of institutional investors in the last quarter, including VHCP Management III LLC, BlackRock Inc., Vanguard Group Inc, Vanguard Group Inc., Bank of New York Mellon Corp, Renaissance Technologies LLC, Sofinnova Ventures Inc and Dimensional Fund Advisors LP. Company insiders that have bought Kadmon stock in the last two years include Daniel S Loeb, Eugene Bauer, Harlan Waksal and Steven N Gordon. View Insider Buying and Selling for Kadmon. How do I buy shares of Kadmon? Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kadmon's stock price today? One share of KDMN stock can currently be purchased for approximately $2.47. How big of a company is Kadmon? Kadmon has a market capitalization of $279.43 million and generates $12.26 million in revenue each year. The company earns $-79,770,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. Kadmon employs 101 workers across the globe. What is Kadmon's official website? The official website for Kadmon is http://www.kadmon.com. How can I contact Kadmon? Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected] MarketBeat Community Rating for Kadmon (NYSE KDMN)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 171 (Vote Outperform)Underperform Votes: 144 (Vote Underperform)Total Votes: 315MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe KDMN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: What is the yield curve?